News & Events
Inmagene has a robust and growing pipeline, focused on treating immunological and inflammatory diseases.
IMG-007 is in two global POC clinical trials. IMG-004 is completing Phase 1 clinical development. IMG-008 is entering global Phase 1 clinical development.
Inmagene has formed strategic partnerships with Affibody AB and HUTCHMED (Nasdaq/AIM: HCM) to develop highly innovative drug candidates.
Inmagene has several highly differentiated assets available for partnering.
News and Events
View all news